文献速递慢性肾脏病水电解质与酸碱

成人慢性肾脏病维生素D治疗:系统评价与Meta分析

Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis.
PubMed 文献 · Am J Kidney Dis · 2023-06-24

该系统评价纳入128项随机对照试验共11270例3至5期慢性肾脏病(含透析)成人患者,评估维生素D治疗对死亡、心血管、骨骼和肾脏结局的影响。与安慰剂相比,维生素D治疗可能对全因死亡无影响(RR 1.04,95%CI 0.84-1.24),对骨折和心血管死亡的影响不确定,但可降低血清甲状旁腺激素和碱性磷酸酶并升高血清钙。

要点

  • 维生素D治疗可能对慢性肾脏病患者的全因死亡无影响(RR 1.04,95%CI 0.84-1.24)。
  • 对骨折(RR 0.68,95%CI 0.37-1.23)和心血管死亡(RR 0.73,95%CI 0.31-1.71)的影响不确定。
  • 维生素D治疗降低血清甲状旁腺激素和碱性磷酸酶,但升高血清钙。

核心结论

  • 维生素D治疗未降低慢性肾脏病患者的全因死亡风险。
  • 维生素D治疗对骨折、心血管和肾脏结局的影响不确定。

研究设计与样本

  • 研究设计为随机对照试验的系统评价与Meta分析,检索MEDLINE、Embase和CENTRAL至2023年2月25日。
  • 纳入随访至少3个月、评估维生素D化合物的随机对照试验,对象为3、4或5期慢性肾脏病成人(包括接受透析的肾衰竭患者),排除肾移植受者。
  • 共纳入128项研究,涉及11270例参与者。
  • 采用随机效应Meta分析汇总治疗估计值,使用Cochrane RoB 2工具评估偏倚风险,采用GRADE评定证据确定性。

主要发现

  • 与安慰剂相比,维生素D治疗可能对全因死亡无影响(RR 1.04,95%CI 0.84-1.24)。
  • 与安慰剂相比,维生素D治疗对骨折的影响不确定(RR 0.68,95%CI 0.37-1.23)。
  • 与安慰剂相比,维生素D治疗对心血管死亡的影响不确定(RR 0.73,95%CI 0.31-1.71)。
  • 与安慰剂相比,维生素D治疗降低血清甲状旁腺激素和碱性磷酸酶,但升高血清钙。

关键数值与推荐

  • 主要评价终点为全因死亡、心血管死亡和骨折。
  • 次要结局包括主要不良心血管事件、住院、骨密度、甲状旁腺切除术、进展至肾衰竭、蛋白尿、估算肾小球滤过率、高钙血症、高磷血症、慢性肾脏病-矿物质和骨异常(CKD-MBD)的生化标志物及多种心血管疾病中间结局指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据受限于随访期短、样本量小和质量欠佳的试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Vitamin D is widely used to manage chronic kidney disease-mineral and bone disorder (CKD-MBD). We evaluated the effects of vitamin D therapy on mortality, cardiovascular, bone, and kidney outcomes in adults with CKD. STUDY DESIGN: Systematic review of randomized controlled trials (RCT) with highly sensitive searching of MEDLINE, Embase, and CENTRAL, through February 25, 2023. SETTING & STUDY POPULATIONS: Adults with stage 3, 4, or 5 CKD, including kidney failure treated with dialysis. Recipients of a kidney transplant were excluded. SELECTION CRITERIA FOR STUDIES: RCTs with≥3 months of follow-up evaluating a vitamin D compound. DATA EXTRACTION: Data were extracted independently by three investigators. ANALYTICAL APPROACH: Treatment estimates were summarized using random effects meta-analysis. Primary review endpoints were all-cause death, cardiovascular death, and fracture. Secondary outcomes were major adverse cardiovascular events, hospitalization, bone mineral density, parathyroidectomy, progression to kidney failure, proteinuria, estimated glomerular filtration rate, hypercalcemia, hyperphosphatemia, biochemical markers of CKD-MBD, and various intermediate outcome measures of cardiovascular disease. Risk of bias was assessed using the Cochrane Risk of Bias (RoB) 2 tool. Evidence certainty was adjudicated using GRADE. RESULTS: Overall, 128 studies involving 11,270 participants were included. Compared with placebo, vitamin D therapy probably had no effect on all-cause death (relative risk [RR], 1.04; 95% CI, 0.84-1.24); and uncertain effects on fracture (RR, 0.68; 95% CI, 0.37-1.23) and cardiovascular death (RR, 0.73; 95% CI, 0.31-1.71). Compared with placebo, vitamin D therapy lowered serum parathyroid hormone and alkaline phosphatase, but increased serum calcium. LIMITATIONS: Data were limited by trials with short-term follow-up periods, small sample size, and the suboptimal quality. CONCLUSIONS: Vitamin D therapy did not reduce the risk of all-cause death in people with CKD. Effects on fracture and cardiovascular and kidney outcomes were uncertain. TRIAL REGISTRATION: Registered at PROSPERO with study number CRD42017057691. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD) is associated with increased risk of death, cardiovascular disease, and fractures. This excess risk is thought to be related to changes in bone and mineral metabolism, leading to the development of CKD-mineral and bone disorder (CKD-MBD) which is characterized by vascular calcification and reduced bone quality. Vitamin D is commonly used in the treatment of this condition. We reviewed randomized controlled trials examining the effect of vitamin D therapy in CKD. We found that vitamin D therapy affects serum biomarkers, including an increase in serum calcium. However, it probably has no effect on risk of all-cause death in CKD, and the effects on other clinical bone, cardiovascular, and kidney outcomes are uncertain.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yeung WG, Palmer SC, Strippoli GFM, et al. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2023. PMID: 37356648. doi:10.1053/j.ajkd.2023.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。